Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
$6.48
$0.46
$2.04
$30.11M0.686,718 shs224,800 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.7911,555 shs638 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$3.26
+2.8%
$3.28
$2.68
$7.18
$17.44M1.333,144 shs51,226 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$13.25
$15.30
$5.80
$22.15
$50.58M-0.06953 shs4 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
0.00%0.00%0.00%0.00%0.00%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%+150.00%
Lipocine Inc. stock logo
LPCN
Lipocine
+1.60%-0.94%-3.94%+5.32%-43.89%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%-1.85%-6.82%+10.42%+60.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
N/AN/AN/AN/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
2.7001 of 5 stars
3.55.00.00.00.00.00.6
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
0.00
N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
3.00
Buy$9.00176.07% Upside
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest LPCN, ZIVO, EVLO, and ANGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/10/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/29/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$8.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
$2.30M0.00N/AN/A$1.32 per share0.00
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$11.20M1.56N/AN/A$3.93 per share0.83
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K3,190.87N/AN/A($0.81) per share-16.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
-$38.81MN/A0.00N/AN/AN/A-47.53%-40.55%N/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$10K-$1.02N/AN/AN/A-26.68%-24.77%8/6/2025 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$4.93N/AN/AN/AN/A-2,240.92%8/12/2025 (Estimated)

Latest LPCN, ZIVO, EVLO, and ANGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2025
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.41N/AN/AN/A$0.23 millionN/A
5/8/2025Q4 2024
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
N/A
20.00
20.00
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
15.64
15.64
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
17.00%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
19.70%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
Lipocine Inc. stock logo
LPCN
Lipocine
6.35%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Angion Biomedica Corp. stock logo
ANGN
Angion Biomedica
330.11 million24.18 millionNot Optionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
Lipocine Inc. stock logo
LPCN
Lipocine
105.35 million5.01 millionNo Data
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
103.82 million2.91 millionNot Optionable

Recent News About These Companies

Harmony Biosciences Holdings
Regencell Bioscience Holdings Ltd RGC
ZIVO Bioscience Announces Uplisting to OTCQB Market
Ideaya Biosciences
Dare Bioscience Inc DARE
Zivo Bioscience Inc (ZIVO) USD0.001
Zivo Bioscience Inc ZIVO
Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Angion Biomedica stock logo

Angion Biomedica NASDAQ:ANGN

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 07/21/2025 09:31 AM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Lipocine stock logo

Lipocine NASDAQ:LPCN

$3.28 +0.11 (+3.34%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$13.25 0.00 (0.00%)
As of 07/18/2025

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.